Do all dry powder inhalers show the same pharmaceutical performance?

International Journal of Clinical Practice

Volumn 59, Issue SUPPL. 149, 2005, Pages 7-12

  Taylor, Anthony ^a   Gustafsson, P ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

Author keywords

Dry powder inhalers; ELECTRONIC LUNG ; Fine particle mass; Inspiratory flow; Pharmaceutical performance; Total emitted dose

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CROMOGLYCATE DISODIUM; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; IPRATROPIUM BROMIDE; SALBUTAMOL;

ACCURACY; DRUG RELEASE; DRY POWDER; FLOW RATE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; PARTICULATE MATTER; POWDER INHALER; PREDICTION; PRIORITY JOURNAL; REVIEW;

EID: 33845443229     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1368-504X.2005.00721.x     Document Type: Review

References (11)

1. de Boer AH, Winter HMI, Lerk CF. Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers. Part 1. Inhalation characteristics, work of breathing and volunteers' preference in dependence of the inhaler resistance. Int J Pharm 1996; 130: 231-44.
2. Steckel H, Müller BW. In vitro evaluation of dry powder inhalers II: Influence of carrier particle size and concentration on in vitro deposition. Int J Pharm 1997; 154: 31-7.
3. Steckel H, Müller BW. In vitro evaluation of dry powder inhalers I: drug deposition of commonly used devices. Int J Pharm 1997; 154: 19-29.
4. Hindle M, Byron PR. Dose emissions from marketed dry powder inhalers. Int J Pharm 1995; 116: 169-77.
5. de Boer AH, Gjaltema D, Hagedoorn P. Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers. Part 2: Effect of peak flow rate (PIFR) and inspiration time on the in vitro drug release from three different types of commercial dry powder inhalers. Int J Pharm 1996; 138: 45-56.
6. Hill LS, Slater AL. A comparison of the performance of two modern multidose dry powder asthma inhalers. Respir Med 1998; 92: 105-10.
7. Prime D, Moore AC, Sykes A, Stone SH. Salmeterol/fluticasone propionate Diskus demonstrates dose proportionality across strengths and consistent dosing compared to individual component Diskus devices. Am J Respir Crit Care Med 2003; 167: A893.
8. de Boer AH, Gjaltema D, Hagedoorn P, Frijlink HW. Comparative in vitro performance evaluation of the Novopulmon 200 Novolizer and budesonid-ratiopharm Jethaler: Two novel budesonide dry powder inhalers. Pharmazie 2004; 59: 692-9.
9. Chew NYK, Chan H-K. In vitro performance and dose uniformity between the Foradile Aerolizer and the Oxis Turbuhaler. J Aerosol Med 2001; 14: 495-501.
10. Prime D, Grant AC, Slater AL, Woodhouse RN. A critical comparison of the dose delivery characteristics of four alternative inhalation devices delivering salbutamol -pressurised metered dose inhaler, Diskus™ inhaler, Diskhaler™ inhaler and Turbuhaler™ inhaler. J Aerosol Med 1999; 12: 75-84.
11. Bisgaard H, Klug B, Sumby BS, Burnell PK. Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma. Eur Respir J 1998; 11: 1111-5.